SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence

Epigenetics

Volumn 7, Issue 5, 2012, Pages 447-457

  Atschekzei, Faranaz ^a   Hennenlotter, Jörg ^b   Jänisch, Stefanie ^a   Großhennig, Anika ^a   Tränkenschuh, Wolfgang ^a   Waalkes, Sandra ^a   Peters, Inga ^a   Dörk, Thilo ^a   Merseburger, Axel S ^a   Stenzl, Arnulf ^b   Kuczyk, Markus A ^a   Serth, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer risk; Dna methylation; Prognosis; Renal cell cancer; Sfrp1

Indexed keywords

BISULFITE; SECRETED FRIZZLED RELATED PROTEIN 1;

ADULT; ARTICLE; AUTOPSY; CANCER RECURRENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PYROSEQUENCING; RECURRENCE FREE SURVIVAL;

EID: 84860581960     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.19614     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58:71-96; PMID:18287387; http://dx.doi.org/10.3322/CA.2007.0010.
2. Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986; 181:125-43; PMID:3737468; http://dx.doi.org/10.1016/S0344-0338(86)80001-2.
3. Pischon T, Lahmann PH, Boeing H, Tjønneland A, Halkjaer J, Overvad K, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006; 118:728-38; PMID:16094628; http://dx.doi.org/10.1002/ijc.21398.
4. van Dijk BA, Schouten LJ, Kiemeney LA, Goldbohm RA, van den Brandt PA. Relation of height, body mass, energy intake and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol 2004; 160:1159-67; PMID:15583368.
5. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005; 114:101-8; PMID:15523697; http://dx.doi.org/10.1002/ijc.20618.
6. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999; 49:8-31.
7. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008; 1785:133-55.
8. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469:539-42; PMID:21248752; http://dx.doi.org/10.1038/nature09639.
9. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2011; 30:1390-401; PMID:21132003; http://dx.doi.org/10.1038/onc.2010.525.
10. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010; 29:2104-17; PMID:20154727; http://dx.doi.org/10.1038/onc.2009.493.
11. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006; 12:6989-97; PMID:17145819; http://dx.doi.org/10.1158/1078-0432.CCR-06-1194.
12. Morris MR, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, et al. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer 2008; 98:496-501; PMID:18195710; http://dx.doi.org/10.1038/sj.bjc.6604180.
13. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, et al. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 2003; 22:6794-801; PMID:14555992; http://dx.doi.org/10.1038/sj.onc.1206914.
14. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006; 66:5021-8; PMID:16707423; http://dx.doi.org/10.1158/0008-5472.CAN-05-3365.
15. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-13; PMID:17932254; http://dx.doi.org/10.1126/science.1145720.
16. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; PMID:17320506; http://dx.doi.org/10.1016/j.cell.2007.01.029.
17. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13:4042-5; PMID:17634527; http://dx.doi.org/10.1158/1078-0432.CCR-06-2316.
18. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007; 13:4740-9; PMID:17699851; http://dx.doi.org/10.1158/1078-0432.CCR-07-0143.
19. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 2007; 26:5680-91; PMID:17353908; http://dx.doi.org/10.1038/sj.onc.1210345.
20. Saini S, Liu J, Yamamura S, Majid S, Kawakami K, Hirata H, et al. Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas. Cancer Res 2009; 69:6815-22; PMID:19723665; http://dx.doi.org/10.1158/0008-5472.CAN-09-1254.
21. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 2005; 32:521-30; PMID:16210093; http://dx.doi.org/10.1053/j.seminoncol. 2005.07.003.
22. Issa JP. Cancer prevention: epigenetics steps up to the plate. Cancer Prev Res (Phila) 2008; 1:219-22; PMID:19138962; http://dx.doi.org/10.1158/1940-6207.CAPR-08-0029.
23. Peters I, Vaske B, Albrecht K, Kuczyk MA, Jonas U, Serth J. Adiposity and age are statistically related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue. Cancer Epidemiol Biomarkers Prev 2007; 16:2526-32; PMID:18086755; http://dx.doi.org/10.1158/1055-9965.EPI-07-0203.
24. Schouten LJ, van Dijk BA, Oosterwijk E, van Engeland M, Hulsbergen-van de Kaa CA, Kiemeney LA, et al. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17:3543-50; PMID:19064569; http://dx.doi.org/10.1158/1055-9965.EPI-08-0321.
25. Wallace K, Grau MV, Levine AJ, Shen L, Hamdan R, Chen X, et al. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev Res (Phila) 2010; 3:1552-64; PMID:21149331; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0047.
26. Belshaw NJ, Elliott GO, Foxall RJ, Dainty JR, Pal N, Coupe A, et al. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer 2008; 99:136-42; PMID:18542073; http://dx.doi.org/10.1038/sj.bjc.6604432.
27. Belshaw NJ, Pal N, Tapp HS, Dainty JR, Lewis MP, Williams MR, et al. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis 2010; 31:1158-63; PMID:20395289; http://dx.doi.org/10.1093/carcin/bgq077.
28. Wong CM, Anderton DL, Smith-Schneider S, Wing MA, Greven MC, Arcaro KF. Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women. Epigenetics 2010; 5:645-55; PMID:20716965; http://dx.doi.org/10.4161/epi.5.7.12961.
29. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics 2011; 6:828-37; PMID:21636973; http://dx.doi.org/10.4161/epi.6.7.16500.
30. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 2008; 3:2656; PMID:18628976; http://dx.doi.org/10.1371/journal.pone.0002656.
31. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97:1330-8; PMID:16174854; http://dx.doi.org/10.1093/jnci/dji275.
32. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006; 119:288-96; PMID:16453286; http://dx.doi.org/10.1002/ijc.21807.
33. Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, et al. Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis 2009; 30:214-21; PMID:19037089; http://dx.doi.org/10.1093/carcin/bgn268.
34. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12:989-95; PMID:16467114; http://dx.doi.org/10.1158/1078-0432.CCR-05-2096.
35. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008; 5:114; PMID:18507500; http://dx.doi.org/10.1371/journal.pmed.0050114.
36. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59; MID:18337604; http://dx.doi.org/10.1056/NEJMra072067.
37. Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, et al. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet 2009; 18:1332-42; PMID:19153073; http://dx.doi.org/10.1093/hmg/ddp033.
38. van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, van Criekinge W, et al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol 2010; 176:575-84; PMID:20042676; http://dx.doi.org/10.2353/ajpath.2010.090442.
39. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7:536-40; PMID:7951326; http://dx.doi.org/10.1038/ng0894-536.
40. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59:5438-42; PMID:10554013.
41. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol 2000; 15:835-42; PMID:10963127.
42. Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 2009; PMID:19966864.
43. Yamada D, Kikuchi S, Williams YN, Sakurai-Yageta M, Masuda M, Maruyama T, et al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer 2006; 118:916-23; PMID:16152585; http://dx.doi.org/10.1002/ijc.21450.
44. Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Tränkenschuh W, et al. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int 2012; In press; PMID:22289415; http://dx.doi.org/10.1111/j.1464-410X.2011.10862.x.
45. Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, et al. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer 2007; 6:49; PMID:17634119; http://dx.doi.org/10.1186/1476-4598-6-49.
46. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104:18654-9; PMID:18003927; http://dx.doi.org/10.1073/pnas.0704652104.
47. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35:146-50; PMID:12866414.
48. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262.
49. Kampstra P. Beanplot: A Boxplot Alternative for Visual Comparison of Distributions. J Stat Softw 2001; 28:1-9.